DI-15-02

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No.			R0038G-DIV					
First Inventor Da		Da	vid Goldstein					
Title	Pyrazole Derivatives - p38 Map Kinse Inhibitors							

Express Mail Label No. | ET 648481815 US (Only for new nonprovisional applications under 37 C.F.R. 1.53(b)) Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) 1. Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 8. Nucleotide and/or Amino Acid Sequence Submission 2. Applicant claims small entity status. (if applicable, all necessary) See 37 CFR 1.27. a.
 ☐ Computer Readable Form 92 [Total Pages з. 🔯 Specification b. Specification Sequence Listing on: (preferred arrangement set forth below) i. CD-ROM or CD-R (2 copies); or - Descriptive title of the Invention - Cross References to Related Applications ii. 🔲 paper - Statement Regarding Fed sponsored R & D c.
 ☐ Statements verifying identity of above copies - Reference to sequence listing, a table, **ACCOMPANYING APPLICATIONS PARTS** or a computer program listing appendix - Background of the Invention Assignment Papers (cover sheet & document(s)) - Brief Summary of the Invention ☑ Power of - Brief Description of the Drawings (if filed) 10. 🔲 37 C.F.R.§3.73(b) Statement - Detailed Description (when there is an assignee) Attorney English Translation Document (if applicable) -- Abstract of the Disclosure 11. Copies of IDS 12. 🛛 Information Disclosure Drawing(s) (35 U.S.C.113) [Total Sheets 1 4. Citations Statement (IDS)/PTO-1449 5. Oath or Declaration [Total Pages | 3 13. 🛛 Preliminary Amendment a. Newly executed (original or copy) Return Receipt Postcard (MPEP 503) 14. 🛛 (Should be specifically itemized) (for a continuation/divisional with Box 18 completed) Certified Copy of Priority Document(s) 15. 🔲 (if foreign priority is claimed) Request and Certification under 35 U.S.C. 122 6. Application Data Sheet. See 37 CFR 1.76 16. 🔲 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: of prior application No: 09/305,737 ☑ Divisional ☐ Continuation-in-part (CIP) □ Continuation Group / Art Unit: 1626 Examiner L. STOCKTON Prior application information: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 17. CORRESPONDENCE ADDRESS 24372 Correspondence address below or \square ☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) **Roche Bioscience** Name Patent Law Dept. M/S A2-250 Address 3401 Hillview Avenue 94304 CA Zip Code City State Palo Alto (650) 855-5322 (650) 855-6995 Fax Country USA Telephone 34,537 Registration No. (Attorney/Agent) Mona Anand Agent) January 11, 2002 Date Signature

Doc.# 116348

F

Į.
ű
L
~
ikij:
THE

r-	Complete if Known									
FEE	Applic	Application Number			New application					
	Filing	Filing Date (he			erewith)					
	First N	First Named Inventor Dav			vid Goldstein					
Pa	Exam	Examiner Name (un			assigned)					
	Group / Art Unit ((una	(unassigned)					
TOTAL AMOUN	Attorn	Attorney Docket No. R0038G-DIV								
II.		FEE CALCULATION (continued)								
1. 🛛	The Commissioner is hereby auti- indicated fees, to charge any add required, or to credit any overpay	3. ADI	DITIONAL Large Entity Fee	. FEES	Small Entity Fee			Fee		
Deposit	Deposit 19,1700			(\$) 130	Code			Description filing fee or oath	Paid	
Number	Account Number 18-1700		105 127	50			-	provisional filing fee		
D	Roche Bioscience		139	130			Non-English spe	ecification		
Deposit Account	3401 Hillview Avenue	1	147	2,520			For filing a reque	est for reexamination		
Name	Palo Alto, CA 94304						Examiner action			
	☐ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17						Requesting publication of SIR after Examiner action			
2. Payment	Payment Enclosed:							oly within first month oly within second		
	☐ Credit card ☐ Money	☐ Other	117	920			month	alv within third month	 	
Crieck L	Order		118	1,440			Extension for reply within third month Extension for reply within fourth			
	FEE CALCULATION		128	1,960		month Extension for reply within fifth month			 	
1. BASIC FILIN			119	320			Notice of Appeal			
Large Entity Sn	•		120	320		Filing a brief in support of an appeal				
	ode (\$)	Fee Paid	121	280			Request for oral	hearing		
101 740	Utility filing fee		138	1,510			Petition to institu proceeding	ite a public use		
106 330	Design filing fee		140	110			Petition to revive	e – unavoidable		
107 510	Plant filing fee		141	1,280			Petition to revive	e – unintentional		
							Utility issue fee (or reissue)			
114 160	Provisional filling fee		143	460			Design issue fee	•		
	tee						Plant issue fee			
	122									
			123	50		Processing fee under 37 CFR 1.17			 	
2. EXTRA CLAIM I		from Fee	126	180		Submission of Information Disclosure Stmt				
Total Claims 33	581	40			Recording each patent assignment per property (times number of properties)					
Independent Claims 1	-3 ** = 0 X 8	4 = 0	146	740				ion after final rejection		
Multiple Dependent	x _	= 0	149	740				nal invention to be		
	Small Entity Fee Fee 5. B		179	740		Request for Continued Examination (RCE)				
	Fee Fee Fee Descriptio Code (\$)	n	169	900				dited examination		
103 18	Claims in exces	s of 20	ŧ				of a design applic	ation	[
102 84	•	ims in excess of 3	1							
104 280	• •	lent claim, if not paid pendent claims over	Other f	ee (sner	fv)					
109 84	original patent	pendent claims over	1 2	Other fee (specify)						
110 18	*Redu	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0								
	SUBTOTAL (2)	(\$) 974.00								
**or number previous	y paid, if greater; For Reissues, see	above								
SUBMITTED BY				Complete (if applicable)						
	Monta Anand	Registration No. Atto	rnev/Acco	04.507			5			
Name (Print/Type)	iney/ngen	, J	.,501							
Signature	1 , love me	\sim d					Date	January 11, 2	.002	

PYRAZOLE DERIVATIVES- p38 MAP KINASE INHIBITORS

David Michael Goldstein Sharada Shenvi Labadie David Mark Rotstein Eric Brian Sjogren Francisco Xavier Talamas

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence and patent application are being deposited with the U.S. Postal Service as "EXPRESS MAIL - POST OFFICE TO ADDRESSEE" under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents, Washington D.C. 20231 on May 5, 1999.

EXPRESS MAIL Mailing Label No.

EH974PP359PN2

Name of Person Mailing CHRIS MYERS

Signature May 5, 1999